Table 2 Apical lesion patient characteristics
| Â | Indiana University | Karolinska University | Total |
|---|---|---|---|
Number of patients | 37 | 52 | 89 |
Gender | |||
 Male | 21 | 23 | 44 |
 Female | 16 | 29 | 45 |
Age at treatment, median (range) | 73 (57–81) | 72 (35–88) |  |
Number of tumors | 37 | 56 | 93 |
Primary lung cancer (NSCLC) | 37 | 30a | 67 |
Metastases | 0 | 22 | 22 |
Tumors | |||
 Right | 21 | 28 | 49 |
 Left | 16 | 28 | 44 |
Volume cc, median (range) | GTV 13 (1–113) | CTV 9.1 (0.10–74.5) |  |
Follow-up months, median (range) | 13 (1–71) | 30 (6.1–72.2) |  |
Total treatment dose (Gy), median (range) | 57 (30–72) | Median 45 Gy in 3 fx BED10 Range: 95–138 Gy |  |
Median dose per fraction (Gy) (range) | 19 (10–24) | 15 (6–17) |  |
Median number of fractions (range) | 3 (3–4) | 3 (3–10) |  |
Number of patients with brachial plexopathy | |||
 Total | 7 | 7 | 14 |
 Grade 2 | 4 | 3 | 7 |
 Grade 3 | 2 | 4 | 6 |
 Grade 4 | 1 | 0 | 1 |
Brachial plexopathy development in months post-SBRT, median (range) | 7 (6–23) | 5.8 (0.7–13) |  |